Table 3 Detailed efficacy results according to the risk groups
From: Stereotactic body radiotherapy for localized prostate cancer – 5-year efficacy results
At mFU of 64 mo | Risk groupa | p value* | ||
|---|---|---|---|---|
Low n = 47 | Intermediate n = 56 | High n = 110 | ||
FU mo | ||||
median | 61 | 64 | 64 | |
range | 16–83 | 12–85 | 10–84 | |
bRFS | ||||
n | 47 | 49 | 88 | |
% | 100 | 87.5 | 80.0 | 0.004 |
actuarial 3-y, % | 100 | 92.7 | 88.8 | |
actuarial 5-y, % | 100 | 89.1 | 80.0 | |
OS | ||||
n | 45 | 53 | 97 | |
% | 95.7 | 94.6 | 88.2 | 0.203 |
actuarial 5-y, % | 97.9 | 96.4 | 88.6 | |